CN108026105B - TGFβ受体拮抗剂 - Google Patents

TGFβ受体拮抗剂 Download PDF

Info

Publication number
CN108026105B
CN108026105B CN201680055202.3A CN201680055202A CN108026105B CN 108026105 B CN108026105 B CN 108026105B CN 201680055202 A CN201680055202 A CN 201680055202A CN 108026105 B CN108026105 B CN 108026105B
Authority
CN
China
Prior art keywords
pyridin
pyrrolo
triazin
amino
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680055202.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108026105A (zh
Inventor
L·S·卡里克里斯南
B·E·芬克
R·M·博尔齐莱里
G·特奴库奴如
H·拉哈曼
J·S·瓦里尔
B·塞沙德里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN108026105A publication Critical patent/CN108026105A/zh
Application granted granted Critical
Publication of CN108026105B publication Critical patent/CN108026105B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680055202.3A 2015-07-23 2016-07-21 TGFβ受体拮抗剂 Active CN108026105B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195854P 2015-07-23 2015-07-23
US62/195,854 2015-07-23
PCT/US2016/043252 WO2017015425A1 (en) 2015-07-23 2016-07-21 Tgf beta receptor antagonists

Publications (2)

Publication Number Publication Date
CN108026105A CN108026105A (zh) 2018-05-11
CN108026105B true CN108026105B (zh) 2020-10-16

Family

ID=56609944

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680055202.3A Active CN108026105B (zh) 2015-07-23 2016-07-21 TGFβ受体拮抗剂

Country Status (6)

Country Link
US (1) US10336761B2 (https=)
EP (1) EP3325484A1 (https=)
JP (1) JP2018520201A (https=)
KR (1) KR20180032611A (https=)
CN (1) CN108026105B (https=)
WO (1) WO2017015425A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
CN111655260A (zh) * 2017-10-26 2020-09-11 南方研究院 作为TGF-β抑制剂的噁二唑和噻二唑
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CA3117838A1 (en) 2018-12-27 2020-07-02 Nexys Therapeutics, Inc. (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途
WO2021147699A1 (zh) * 2020-01-21 2021-07-29 四川科伦博泰生物医药股份有限公司 吡啶并杂环类化合物、其制备方法及用途
CN113620956B (zh) * 2020-05-06 2023-06-13 赛诺哈勃药业（成都）有限公司 转化生长因子受体拮抗剂、其制备方法和应用
AU2023249795A1 (en) * 2022-04-08 2024-10-17 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US20260028365A1 (en) * 2022-07-14 2026-01-29 Biogen Ma Inc. Tyrosine kinase 2 inhibitors and uses thereof
EP4651950A1 (en) * 2023-01-19 2025-11-26 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497444C (en) * 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2006521398A (ja) * 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
MX2013010163A (es) * 2011-03-09 2013-10-30 Merck Patent Gmbh Derivados de pirido[2,3-b] pirazina y sus usos terapeuticos.
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands

Also Published As

Publication number Publication date
JP2018520201A (ja) 2018-07-26
EP3325484A1 (en) 2018-05-30
US10336761B2 (en) 2019-07-02
US20180215761A1 (en) 2018-08-02
KR20180032611A (ko) 2018-03-30
CN108026105A (zh) 2018-05-11
WO2017015425A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
CN108026105B (zh) TGFβ受体拮抗剂
TWI848954B (zh) 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
CN112105419B (zh) 稠环化合物
JP6675501B2 (ja) 抗がん剤としての三環式化合物
JP7051829B2 (ja) Ｄｎｍｔ１の阻害剤としての置換ピリジン
JP5832524B2 (ja) ピリドン及びアザピリドン化合物、並びにそれらの使用方法
TWI726968B (zh) Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
CN107857755B (zh) 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
JP2022071046A (ja) Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
US9708316B2 (en) TGFβR antagonists
JP2022548822A (ja) がんの治療における使用のためのヘテロ環式化合物
CN112105385A (zh) Irak降解剂和其用途
TWI845638B (zh) Ｅｅｄ及ｐｒｃ２調節劑之巨環唑并吡啶衍生物
TW201819376A (zh) 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
CN103298468A (zh) 稠环杂环衍生物
TW201639827A (zh) ＴＧＦ－β抑制劑
KR20170040300A (ko) 2-(모르폴린-4-일)-l,7-나프티리딘
TW201444849A (zh) 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
CN107709322A (zh) 作为抗癌剂的三环化合物
CN113072551A (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
CN105246890A (zh) 吡咯并[2,3-b]吡啶cdk9激酶抑制剂
WO2020216378A1 (zh) 一种含杂环的化合物、其应用及含其的组合物
IL316254A (en) Pyrido[D-3,2]pyrimidines and their use as HPK1 inhibitors
HK40129387A (zh) 造血前驱细胞激酶1的吡啶酮及嘧啶酮抑制剂
HK40046970B (zh) 新型杂原子芳香族酰胺衍生物以及含有其的药剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant